Dianthus Therapeutics, Inc. /DE/ (DNTH) earnings date
Mar 9, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 15 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Mon, Mar 9, 2026 | before open | 68 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q4 FY2024 | Tue, Mar 11, 2025 | after close | 70 | 8-K |
What they guided beta
| Q3 FY2026 | "Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q3 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in 2H’28" exhibit |
| Q3 FY2026 | "Phase 3 CAPTIVATE trial of claseprubart in CIDP evaluating 300mg/2mL Q2W now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study, with Part A top-line results expected by YE’27 and Part B top-line results expected by YE’28 Phase 2 MoMeNtum trial of claseprubart in MMN top-line results on track for December ’26 DNTH212 continues to advance with Phase 1 single ascending dose (SAD) Part A healthy volunteer preliminary data expected in Q1’27." exhibit |
| Q3 FY2026 | "The Dianthus-led Phase 1 multiple ascending dose (MAD) study is planned to initiate in Q2’27 with preliminary data expected in 2H’27 DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases, on track to be Phase 1 ready by YE’27 Approximately $1.2 billion of cash as of September 30, 2026 provides expected runway into 2030 New York City and Waltham, Mass., November 4, 2026 – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechn" exhibit |
| Q3 FY2026 | "Part A is evaluating single ascending doses of DNTH212, with preliminary healthy volunteer data expected in Q1’27." exhibit |
| Q3 FY2026 | "Dianthus-led MAD study planned to initiate in Q2’27: Dianthus plans to initiate a Phase 1 multiple ascending dose (MAD) study outside of China in healthy volunteers in Q2’27 to support the continued global development of DNTH212, with preliminary data expected in 2H’27." exhibit |
| Q2 FY2026 | "75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE’26 Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December ’26 Building a rheumatology franchise with DNTH212 across our first three prioritized indications of Sjögren’s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM); Phase 1 healthy volunteer data anticipated by YE’2" exhibit |
| Q2 FY2026 | "Cash Position – Approximately $1.2 billion of cash, cash equivalents and investments as of June 30, 2026 is projected to provide runway into 2030." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DNTH
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DNTH
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/DNTH/"><img src="https://veritasdata.dev/embed/DNTH.svg" alt="DNTH earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/DNTH/)
Script
<script async src="https://veritasdata.dev/embed/DNTH.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DNTH"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.